HK:6996 Stock Latest News
Company AnnouncementsAntengene Grants 11.52 Million RSUs Under 2022 Incentive Scheme1M ago
Company AnnouncementsAntengene Wins Australian Approval to Begin Phase I Trial of Autoimmune Drug ATG-2012M ago
Company AnnouncementsAntengene Swings to Interim Profit on Licensing-Driven Revenue Surge2M ago
Company AnnouncementsAntengene Sets Board Meeting to Approve 2026 Interim Results2M ago
Company AnnouncementsAntengene Updates Board Composition and Committee Roles3M ago
Company AnnouncementsAntengene Reshapes Leadership Team With CFO Exit and New Executive Appointments3M ago
Company AnnouncementsAntengene Launches HK$50 Million Share Buyback Plan4M ago
Company AnnouncementsAntengene Out-Licenses ATG-106 to K2 Therapeutics in Potential US$1.9 Billion TCE Deal4M ago- Company AnnouncementsAntengene Reshuffles Joint Company Secretaries to Strengthen Governance Compliance4M ago
- Company AnnouncementsAntengene Shareholders Back All AGM Resolutions, Bolstering Capital Flexibility4M ago
Company AnnouncementsAntengene Wins China IND Nod for ATG-201 Autoimmune Trial4M agoCompany AnnouncementsAntengene Wins China IND Nod for Pivotal Phase III Trial of ATG-022 in Advanced Gastric Cancer5M ago
Company AnnouncementsAntengene Names New Chief Scientific Officer to Drive Next-Generation R&D Pipeline5M ago
- Company AnnouncementsAntengene Moves to Modernize Governance as Global Oncology Portfolio Expands6M ago
Company AnnouncementsAntengene Sets 2026 AGM to Renew Governance Mandates and Share Issuance Authority6M ago
Company AnnouncementsAntengene Grants 1.9 Million Share Options and RSUs to Reward Key Talent6M ago- Company AnnouncementsAntengene Executives Boost Stakes in Vote of Confidence on Long-Term Growth7M ago
Company AnnouncementsAntengene Narrows Losses on Cost Cuts as Revenue Climbs in 20257M ago
Company AnnouncementsAntengene Grants UCB Global Rights to ATG-201 in Autoimmune Disease Deal Worth Up to USD1.2 Billion8M ago